(Q73948189)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

B Eriksson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

J Renstrup

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

H Imam

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

K Oberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 October 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

1041-1044

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205415035

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008205415035

1 reference

7 January 2021

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205415035

7 January 2021

Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205415035

7 January 2021

Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205415035

7 January 2021

Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205415035

7 January 2021

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205415035

7 January 2021

Identifiers

DOI

10.1023/A:1008205415035

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9402179%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference